|
|
1.
|
THERAPEUTIC APPLICATION OF 64CU-LABELLED CONJUGATES FOR SITE-SPECIFIC UPAR-TARGETING
| Application Number |
EP2025069923 |
| Publication Number |
2026/013269 |
| Status |
In Force |
| Filing Date |
2025-07-11 |
| Publication Date |
2026-01-15 |
| Owner |
CURASIGHT A/S (Denmark)
|
| Inventor |
Kjær, Andreas
|
Abstract
The present invention provides Therapeutic application of 64Cu labelled uPAR binding conjugates for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) in treatment of cancer diseases associated with high uPAR expression.
|
2.
|
UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCCS)
| Application Number |
18714514 |
| Status |
Pending |
| Filing Date |
2022-11-29 |
| First Publication Date |
2025-10-16 |
| Owner |
Curasight A/S (Denmark)
|
| Inventor |
Kjær, Andreas
|
Abstract
The present invention relates to the a positron-emitting imaging agent for use in the prognosis of a head and neck cancer (HNSCC) in a subject by PET imaging of the cancer, wherein said imaging agent comprises a uPAR binding peptide coupled via the chelating agent NOTA or DOTA to the radionuclide 68Ga or 64Cu.
|
3.
|
UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS
| Application Number |
18719602 |
| Status |
Pending |
| Filing Date |
2022-12-15 |
| First Publication Date |
2025-02-13 |
| Owner |
Curasight A/S (Denmark)
|
| Inventor |
Kjær, Andreas
|
Abstract
The present invention relates to positron-emitting imaging agents for use in the prognosis of a neuroendocrine neoplasm (NEN) patient in by PET imaging of the cancer, wherein said imaging agent comprises a uPAR binding peptide coupled via the chelating agent NOTA or DOTA to the radionuclide 68Ga or 64Cu. The invention also relates to compositions comprising a radiopharmaceutical for use in the treatment or alleviation of a neuroendocrine neoplasm (NEN) in a subject, wherein said radiopharmaceutical comprises a radionuclide and a uPAR binding peptide.
|
4.
|
UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN BRAIN TUMOURS
| Document Number |
03296634 |
| Status |
Pending |
| Filing Date |
2024-06-26 |
| Open to Public Date |
2025-01-02 |
| Owner |
CURASIGHT A/S (Denmark)
|
| Inventor |
Kjær, Andreas
|
|
5.
|
UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN BRAIN TUMOURS
| Application Number |
EP2024067906 |
| Publication Number |
2025/003190 |
| Status |
In Force |
| Filing Date |
2024-06-26 |
| Publication Date |
2025-01-02 |
| Owner |
CURASIGHT A/S (Denmark)
|
| Inventor |
Kjær, Andreas
|
Abstract
The present invention relates to positron-emitting imaging agents for use in the prognosis of brain tumours in a patient by PET imaging of the cancer, wherein said imaging agent comprises an uPAR binding peptide coupled to a radionuclide. The invention also relates to compositions comprising a radiopharmaceutical for use in the treatment or alleviation of a brain tumour in a subject, wherein said radiopharmaceutical comprises a radionuclide and an uPAR binding peptide.
|
6.
|
RADIONUCLIDE LABELLED PEPTIDE CONJUGATE FOR SITE-SPECIFIC UPAR-TARGETING
| Document Number |
03280172 |
| Status |
Pending |
| Filing Date |
2024-01-18 |
| Open to Public Date |
2024-07-25 |
| Owner |
CURASIGHT A/S (Denmark)
|
| Inventor |
Kjær, Andreas
|
|
7.
|
RADIONUCLIDE LABELLED PEPTIDE CONJUGATE FOR SITE-SPECIFIC UPAR-TARGETING
| Application Number |
EP2024051181 |
| Publication Number |
2024/153756 |
| Status |
In Force |
| Filing Date |
2024-01-18 |
| Publication Date |
2024-07-25 |
| Owner |
CURASIGHT A/S (Denmark)
|
| Inventor |
Kjær, Andreas
|
Abstract
The present invention provides a radionuclide labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) and treatment of cancer diseases associated with high uPAR expression.
|
8.
|
CURASIGHT
| Application Number |
231853500 |
| Status |
Pending |
| Filing Date |
2024-03-07 |
| Owner |
CURASIGHT A/S (Denmark)
|
| NICE Classes ? |
- 05 - Pharmaceutical, veterinary and sanitary products
- 42 - Scientific, technological and industrial services, research and design
|
Goods & Services
(1) Diagnostic reagents for medical purposes for prevention, detection, diagnosis and treatment of cancer. (1) Research and development of diagnostic reagents for medical purposes in the field of prevention, detection, diagnosis and treatment of cancer.
|
9.
|
UTRACE
| Serial Number |
79392699 |
| Status |
Registered |
| Filing Date |
2024-03-07 |
| Registration Date |
2025-02-18 |
| Owner |
CURASIGHT A/S (Denmark)
|
| NICE Classes ? |
05 - Pharmaceutical, veterinary and sanitary products
|
Goods & Services
Diagnostic preparations for medical purposes
|
10.
|
CURASIGHT
| Serial Number |
79392700 |
| Status |
Registered |
| Filing Date |
2024-03-07 |
| Registration Date |
2025-01-07 |
| Owner |
CURASIGHT A/S (Denmark)
|
| NICE Classes ? |
- 05 - Pharmaceutical, veterinary and sanitary products
- 42 - Scientific, technological and industrial services, research and design
|
Goods & Services
Diagnostic preparations for medical purposes Research and development of diagnostic preparations for medical purposes
|
11.
|
UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR TARGETED RADIOLABELED PEPTIDE CONJUGATES
| Application Number |
18039542 |
| Status |
Pending |
| Filing Date |
2021-11-26 |
| First Publication Date |
2024-01-11 |
| Owner |
CURASIGHT A/S (Denmark)
|
| Inventor |
- Kjaer, Andreas
- Jensen, Knud Jorgen
- Madsen, Jakob
- Jeppesen, Troels Elmer
|
Abstract
The present invention describes Urokinase Plasminogen Activator Receptor (uPAR) targeted radiolabeled conjugates suited for non-invasive PET imaging, SPECT imaging or targeted radionuclide therapy. In particular, but not limited to, the invention related to imaging and therapy of cancer diseases.
|
12.
|
UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS
| Document Number |
03241038 |
| Status |
Pending |
| Filing Date |
2022-12-15 |
| Open to Public Date |
2023-06-22 |
| Owner |
CURASIGHT A/S (Denmark)
|
| Inventor |
Kjar, Andreas
|
Abstract
The present invention relates to positron-emitting imaging agents for use in the prognosis of a neuroendocrine neoplasm (NEN) patient in by PET imaging of the cancer, wherein said imaging agent comprises a uPAR binding peptidecoupled via the chelating agent NOTA or DOTA to the radionuclide 68Ga or 564Cu. The invention also relates to compositions comprising a radiopharmaceutical for use in the treatment or alleviation of a neuroendocrine neoplasm (NEN) in a subject, wherein said radiopharmaceutical comprises a radionuclide and a uPAR binding peptide.
|
13.
|
UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS
| Application Number |
EP2022086147 |
| Publication Number |
2023/111176 |
| Status |
In Force |
| Filing Date |
2022-12-15 |
| Publication Date |
2023-06-22 |
| Owner |
CURASIGHT A/S (Denmark)
|
| Inventor |
Kjær, Andreas
|
Abstract
The present invention relates to positron-emitting imaging agents for use in the prognosis of a neuroendocrine neoplasm (NEN) patient in by PET imaging of the cancer, wherein said imaging agent comprises a uPAR binding peptidecoupled via the chelating agent NOTA or DOTA to the radionuclide 68Ga or 564Cu. The invention also relates to compositions comprising a radiopharmaceutical for use in the treatment or alleviation of a neuroendocrine neoplasm (NEN) in a subject, wherein said radiopharmaceutical comprises a radionuclide and a uPAR binding peptide.
|
14.
|
UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCCS)
| Application Number |
EP2022083665 |
| Publication Number |
2023/099472 |
| Status |
In Force |
| Filing Date |
2022-11-29 |
| Publication Date |
2023-06-08 |
| Owner |
CURASIGHT A/S (Denmark)
|
| Inventor |
Kjær, Andreas
|
Abstract
The present invention relates to the a positron-emitting imaging agent for use in the prognosis of a head and neck cancer (HNSCC) in a subject by PET imaging of the cancer, wherein said imaging agent comprises a uPAR bindingpeptide coupled via the chelating agent NOTA or DOTA to the radionuclide 568Ga or 64Cu.
|
15.
|
Positron emitting radionuclide labeled peptides for human uPAR PET imaging
| Application Number |
17697485 |
| Grant Number |
12409240 |
| Status |
In Force |
| Filing Date |
2022-03-17 |
| First Publication Date |
2022-06-30 |
| Grant Date |
2025-09-09 |
| Owner |
CURASIGHT A/S (Denmark)
|
| Inventor |
- Kjaer, Andreas
- Persson, Morten
- Madsen, Jacob
|
Abstract
There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
|
16.
|
Positron emitting radionuclide labeled peptides for human uPAR PET imaging
| Application Number |
16870776 |
| Grant Number |
11311637 |
| Status |
In Force |
| Filing Date |
2020-05-08 |
| First Publication Date |
2020-08-27 |
| Grant Date |
2022-04-26 |
| Owner |
Curasight A/S (Denmark)
|
| Inventor |
- Kjaer, Andreas
- Persson, Morten
- Madsen, Jacob
|
Abstract
There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
|
17.
|
uTREAT
| Application Number |
201197100 |
| Status |
Registered |
| Filing Date |
2020-01-15 |
| Registration Date |
2021-09-22 |
| Owner |
CURASIGHT A/S (Denmark)
|
| NICE Classes ? |
05 - Pharmaceutical, veterinary and sanitary products
|
Goods & Services
(1) Medical preparations for treating cancer.
|
18.
|
UTREAT
| Serial Number |
79278896 |
| Status |
Registered |
| Filing Date |
2020-01-15 |
| Registration Date |
2020-07-21 |
| Owner |
CURASIGHT A/S (Denmark)
|
| NICE Classes ? |
05 - Pharmaceutical, veterinary and sanitary products
|
Goods & Services
Medical preparations for treating cancer
|
19.
|
uTREAT
| Application Number |
1505325 |
| Status |
Registered |
| Filing Date |
2019-09-25 |
| Registration Date |
2019-09-25 |
| Owner |
CURASIGHT A/S (Denmark)
|
| NICE Classes ? |
05 - Pharmaceutical, veterinary and sanitary products
|
Goods & Services
Medical preparations for treating cancer.
|
20.
|
uTRACE
| Application Number |
198964700 |
| Status |
Registered |
| Filing Date |
2019-09-26 |
| Registration Date |
2021-11-17 |
| Owner |
CURASIGHT A/S (Denmark)
|
| NICE Classes ? |
05 - Pharmaceutical, veterinary and sanitary products
|
Goods & Services
(1) Diagnostic preparations for medical purposes.
|
21.
|
CURASIGHT
| Application Number |
1319863 |
| Status |
Registered |
| Filing Date |
2016-08-29 |
| Registration Date |
2016-08-29 |
| Owner |
CURASIGHT A/S (Denmark)
|
| NICE Classes ? |
- 05 - Pharmaceutical, veterinary and sanitary products
- 42 - Scientific, technological and industrial services, research and design
|
Goods & Services
Diagnostic preparations for medical purposes. Research and development of diagnostic preparations for
medical purposes.
|
22.
|
uTRACE
| Application Number |
1317560 |
| Status |
Registered |
| Filing Date |
2016-08-29 |
| Registration Date |
2016-08-29 |
| Owner |
CURASIGHT A/S (Denmark)
|
| NICE Classes ? |
05 - Pharmaceutical, veterinary and sanitary products
|
Goods & Services
Diagnostic preparations for medical purposes.
|
23.
|
POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING
| Document Number |
03106713 |
| Status |
In Force |
| Filing Date |
2013-11-29 |
| Open to Public Date |
2014-06-12 |
| Grant Date |
2024-01-09 |
| Owner |
CURASIGHT A/S (Denmark)
|
| Inventor |
- Kjaer, Andreas
- Persson, Morten
- Madsen, Jacob
|
Abstract
Abstract There is provided a positron-emitting radionuclide labelled peptide for non- invasive PET imaging of the Urok-inase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence. Date Recue/Date Received 2021-01-21
IPC Classes ?
- A61K 51/08 - Peptides, e.g. proteins
- C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
|
24.
|
POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING
| Document Number |
02903261 |
| Status |
In Force |
| Filing Date |
2013-11-29 |
| Open to Public Date |
2014-06-12 |
| Grant Date |
2021-03-09 |
| Owner |
CURASIGHT A/S (Denmark)
|
| Inventor |
- Kjaer, Andreas
- Persson, Morten
- Madsen, Jacob
|
Abstract
There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
|
|
